Endocrinology and Metabolism

Original Articles

Diabetes, obesity and metabolism
Efficacy and Safety of Omarigliptin, a Novel Once-Weekly Dipeptidyl Peptidase-4 Inhibitor, in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis: A.B.M. Kamrul-Hasan, Muhammad Shah Alam, Samir Kumar Talukder, Deep Dutta, Shahjada Selim; Endocrinol Metab. 2024;39(1):109-126. Published online January 23, 2024; DOI: https://doi.org/10.3803/EnM.2023.1839

1,191 View
40 Download

Abstract PDF Supplementary Material PubReader ePub: Background
No recent meta-analysis has holistically analyzed and summarized the efficacy and safety of omarigliptin in type 2 diabetes mellitus (T2DM). We conducted a meta-analysis to address this knowledge gap.
Methods
Electronic databases were searched to identify randomized controlled trials (RCTs) that included patients with T2DM who received omarigliptin in the intervention arm. The control arm consisted of either a placebo (passive control group [PCG]) or an active comparator (active control group [ACG]). The primary outcome assessed was changes in hemoglobin A1c (HbA1c), while secondary outcomes included variations in glucose levels, achievement of glycemic targets, adverse events (AEs), and hypoglycemic events.
Results
From 332 initially screened articles, data from 16 RCTs involving 8,804 subjects were analyzed. Omarigliptin demonstrated superiority over placebo in reducing HbA1c levels (mean difference, –0.58%; 95% confidence interval, –0.75 to –0.40; P<0.00001; I²=91%). Additionally, omarigliptin outperformed placebo in lowering fasting plasma glucose, 2-hour postprandial glucose, and in the percentage of participants achieving HbA1c levels below 7.0% and 6.5%. The glycemic efficacy of omarigliptin was similar to that of the ACG across all measures. Although the omarigliptin group experienced a higher incidence of hypoglycemic events compared to the PCG, the overall AEs, serious AEs, hypoglycemia, and severe hypoglycemia were comparable between the omarigliptin and control groups (PCG and ACG).
Conclusion
Omarigliptin has a favorable glycemic efficacy and safety profile for managing T2DM.

Clinical Study Big Data Articles (National Health Insurance Service Database)
Effect of Teneligliptin versus Sulfonylurea on Major Adverse Cardiovascular Outcomes in People with Type 2 Diabetes Mellitus: A Real-World Study in Korea: Da Hea Seo, Kyoung Hwa Ha, So Hun Kim, Dae Jung Kim; Endocrinol Metab. 2021;36(1):70-80. Published online February 24, 2021; DOI: https://doi.org/10.3803/EnM.2020.777

4,976 View
192 Download
5 Web of Science
4 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Results regarding the cardiovascular (CV) effects of dipeptidyl peptidase-4 (DPP-4) inhibitors are inconsistent. This study aimed to assess the effects of teneligliptin, a DPP-4 inhibitor, on the risk of major CV outcomes in type 2 diabetes mellitus (T2DM) patients compared to sulfonylurea.
Methods
From January 1, 2015 to December 31, 2017, we conducted a retrospective cohort study using the Korean National Health Insurance Service database. A total of 6,682 T2DM patients who were newly prescribed DPP-4 inhibitors or sulfonylurea were selected and matched in a 1:1 ratio by propensity score. The hazard ratios (HRs) for all-cause mortality, hospitalization for heart failure (HHF), all-cause mortality or HHF, myocardial infarction (MI), stroke, and hypoglycemia were assessed.
Results
During 641 days of follow-up, the use of teneligliptin was not associated with an increased risk of all-cause mortality (HR, 1.00; 95% confidence interval [CI], 0.85 to 1.19), HHF (HR, 0.99; 95% CI, 0.86 to 1.14), all-cause mortality or HHF (HR, 1.02; 95% CI, 0.90 to 1.14), MI (HR, 0.90; 95% CI, 0.68 to 1.20), and stroke (HR, 1.00; 95% CI, 0.86 to 1.17) compared to the use of sulfonylurea. However, it was associated with a significantly lower risk of hypoglycemia (HR, 0.68; 95% CI, 0.49 to 0.94) compared to sulfonylurea therapy.
Conclusion
Among T2DM patients, teneligliptin therapy was not associated with an increased risk of CV events including HHF, but was associated with a lower risk of hypoglycemia compared to sulfonylurea therapy.

Citations

Citations to this article as recorded by

Association between age at diagnosis of type 2 diabetes and cardiovascular morbidity and mortality risks: A nationwide population-based study
Da Hea Seo, Mina Kim, Young Ju Suh, Yongin Cho, Seong Hee Ahn, Seongbin Hong, So Hun Kim
Diabetes Research and Clinical Practice.2024; 208: 111098. CrossRef
Systematic review and meta-analysis of teneligliptin for treatment of type 2 diabetes
R. Pelluri, S. Kongara, V. R. Nagasubramanian, S. Mahadevan, J. Chimakurthy
Journal of Endocrinological Investigation.2023; 46(5): 855. CrossRef
Finding the most cost-effective option from commonly used Dipeptidyl peptidase-4 inhibitors in India: a systematic study
Harmanjit Singh, Ekta Arora, Seerat Narula, Mandeep Singla, Armaan Otaal, Jatin Sharma
Expert Review of Endocrinology & Metabolism.2023; 18(4): 347. CrossRef
Association Between DPP4 Inhibitor Use and the Incidence of Cirrhosis, ESRD, and Some Cancers in Patients With Diabetes
Yewon Na, Soo Wan Kim, Ie Byung Park, Soo Jung Choi, Seungyoon Nam, Jaehun Jung, Dae Ho Lee
The Journal of Clinical Endocrinology & Metabolism.2022; 107(11): 3022. CrossRef

Case Reports

A Case with Isolated ACTH Deficiency.: Myoung Sik Kim, Byung Doo Lee, Sang Min Shin, Young Il Kim, Byung Oh Jeong, Hong Jib Choi, Phil Ho Kim, Kyung Soo Ko, Jae Hong Park; J Korean Endocr Soc. 1996;11(4):538-543. Published online November 7, 2019

1,202 View
51 Download

Abstract PDF: Isolated ACTH deficiency is a rare cause of secondary adrenocortical insufficiency. Adrenal crisis in isolated ACTH deficiency is less common compared to primary adrenal insufficiency, but isolated ACTH deficiency is an important cause of hypoglycemia. Recently we experienced a 41-year-old man admitted because of mental confusion. On admission, plasma glucose and sodium concentration were 1.7, 132 mmol/L, respectively. Basal plasma ACTH and cortisol levels were low and other pituitary hormone showed normal response to combined pituitary stimulation test except growth hormone. Plasma ACTH concentration remained low even after intravenous injection of ovine corticotropin releasing factor. It suggest that the defect of ACTH secretion was apparently due to intrinsic pituitary rather than hypothalamic disease. The sellar CT showed the fossa to be filled by cerebrospinal fluid. After treatment with glucocorticoid, he had no further evidence of hypoglycemia and hyponatremia. In conclusion, we report a case of isolated ACTH deficiency with empty sella.

Diffuse Nesidioblastosis of the Pancreasin Adult with Persistent Hyperinsulinemic Hypoglycemia.: Seoung Ha Lee, Kean Young Hyoung, Geom Seog Seo, Bong Joo Shin, Chung Gu Cho, Kwang Soo Yang, Kwon Mook Chae, Ki Jung Yun; J Korean Endocr Soc. 1996;11(2):247-253. Published online November 7, 2019

1,033 View
19 Download

Abstract PDF: Nesidioblastosis is a term that describes multifocal hyperplasia of all panereatic cell components and is characterized primarily by their disorganization and proliferation throughout the entire panaeas. Adult onset nesidioblastosis is an extremely rare entity associated with hypersecretion of insulin. The authors have recently experieneed a case of nesidioblastosis in an adult. A 41-year old man was admitted due to interrnittenr hypoglycemic symptoms, that had been relieved by carbohydrate ingestion. Hyperinsulinemic hypoglycemia was documented during prolonged fast. Under the presumptive diagnosis of insulinoma, abdominal CT, celiac angiogram and percutaneous transhepatic portal venous sampling were done but we could not find any definitive mass. Eight-five percent of the panacas was removed. Pathologic examination of the resected pancreas revealed irregularly sized islets and scattering of small endocrine cell clusters throughout the acinar tissue and ductuloinsular complex.

Two Cases of hypoglycemia in IDDM patients with insulin antibody.: G A Kim, K W Lee, M R Kim, Y J Kim, J N Jang, S K Bae, B G Son; J Korean Endocr Soc. 1996;11(2):240-246. Published online November 7, 2019

1,024 View
19 Download

Abstract PDF: Hirata et al. first described the association of insulin antibodies with hypoglycemia attacks and decreased glucose tolerance in a patient who had not previously received insulin injections. Since that time there have been additional reports in the Japanese literature. Insulin antibodies are present in most of the patients who received insulin for a period of time, usually exceeding six weeks. There were several reports of hypoglycemia in patients with non-insulin-dependent diabetes mellitus who had developed insulin antibody after insulin administration and also in patients with insulin dependent diabetes mellitus. It is well known that either insulin antibody to the lower affinity site or insulin receptor antibody can be a eause of hypoglycemia. Recently, we experienced two cases of hypoglycemia in patient with insulin dependent diabetes rnellitus and non- insulin- dependent diabetes mellitus who had developed insulin antibody after insulin administration. Hereby we present these cases with review of the literature.

A Case of Non - Islet Cell Tumor Hypoglycemia.: Moon Hee Lee, Seung Sik Kang, Jin Lee, Sung Hee Ihm, Jae Myung Yoo, Moon Gi Choi, Hyung Joon Yoo, Sung Woo Park; J Korean Endocr Soc. 1995;10(1):65-69. Published online November 6, 2019

1,146 View
32 Download

Abstract PDF: The association between non-islet cell tumors and fasting hypoglycemia has been recognized since 1929. The humoral mediator of this non-islet cell tumor hypoglycemia(NICTH) is now known as IGF-II. Hypoglycemia develops commonly in the course of hepatocellular carcinoma(HCC), mostly late in the course and usually mild to moderate in severity. Rarely, severe hypoglycemia occurs early in the course of HCC, suggesting NICTH. We report a case of HCC in which hypoglycemic coma due to NICTH was the presenting symptom.A 52-year-old man developed mental confusion and seizures in the early morning. At emergency room, he was found to have severe hypoglycemia. Circulating levels of insulin, C-peptide, insulinlike growth factor-I(IGF-I) and growth hormone were reduced during hypoglycemia. Diagnostic work-up revealed that he had unresectable HCC. During admission, infusion of more than 400g of dextrose per day in addition to meals was required to prevent hypoglycemia. Because the chemotherapy was refused, he was transferred to a local hospital to receive infusions of dextrose.

A Case of Nesidioblastosis in Adult with Hyperinsulinemic Hypoglycemia.: Young Kee Shong, Hong Kyu Kim, Young Joo Min, Joong Yeol Park, Sung Kwan Hong, Ki Up Lee, Duck Jong Han, Ho Jeong Lee, Ghi Su Kim, Gyung Yub Gong; J Korean Endocr Soc. 1994;10(3):273-277. Published online November 6, 2019

1,087 View
20 Download

Abstract PDF: Nesidioblastosis is a primarily childhood disease which is often associated with hyperinsulinemic hypoglycemia. It is very rarely found in adults. Only a few well documented cases are found in the world interature. The authors have recently experienced a case of nesidioblastosis in an adult. A 55-year-old man was admitted due to repeated episodes of reversible loss of consciousness. Hyperinsulinemic hypoglycemia was documented. Under the presumptive diagnosis of insulinoma, localization procedures were done but no definite tumor was found. Only suspicious gradient in insulin concentration was found around the head of pancreas by percutaneous transhepatic portal venous sampling. Exploratory laparotomy was performed and Whipple's operation was done. Seventy percent of proximal pancreas was removed. Histomorphometric study of the resected specimen revealed uneven graded hyperplasia of the islet cells with the most profuse hyperplasia in the head region and progressive decrease in the degree of hyperplasia to the body and tail. The patient remains euglycemia until 6 months after operation since immediate postoperative period and can tolerate 24 hour fasting without any medication.

Original Articles

Clinical Study
Impaired Cortisol and Growth Hormone Counterregulatory Responses among Severe Hypoglycemic Patients with Type 2 Diabetes Mellitus: Young A Rhyu, Ju-Young Jang, Sooyoun Park, Jee Hyun An, Dong-Lim Kim, Suk Kyeong Kim, Kee-Ho Song; Endocrinol Metab. 2019;34(2):187-194. Published online June 24, 2019; DOI: https://doi.org/10.3803/EnM.2019.34.2.187

5,007 View
75 Download
10 Web of Science
12 Crossref

Abstract PDF PubReader ePub

Background

Elevated levels of cortisol and growth hormone are critical counterregulatory responses to severe hypoglycemia. However, the proportion and clinical characteristics of patients with type 2 diabetes mellitus (DM) who fail to show appropriate cortisol and/or growth hormone secretion in response to severe hypoglycemia have not been investigated.

Methods

We measured plasma cortisol and growth hormone levels in type 2 DM patients with severe hypoglycemia who visited the emergency department between 2006 and 2015.

Results

Of 112 hypoglycemic patients, 23 (20.5%) had an impaired cortisol response (<18 µg/dL) and 82 patients (73.2%) had an impaired growth hormone response (<5 ng/mL). Nineteen patients (17.0%) had impaired responses to both cortisol and growth hormone. The patients with impaired responses of cortisol, growth hormone, and both hormones were significantly older and more likely to be female, and had higher admission rates, lower growth hormone levels, and lower adrenocorticotropic hormone levels than the patients with a normal hormonal response. Multivariate logistic regression analysis indicated that an impaired growth hormone response was significantly associated with advanced age, shorter DM duration, a higher admission rate, and a higher body mass index (BMI). An impaired cortisol response was significantly associated with growth hormone levels. Patients with an impaired growth hormone response had higher admission rates than patients with a normal response.

Conclusion

A considerable number of type 2 DM patients had impaired cortisol and/or growth hormone responses to severe hypoglycemia. Advanced age, shorter DM duration, and higher BMI were independently associated with an abnormal growth hormone response.

Citations

Citations to this article as recorded by

The deleterious effects of sofosbuvir and ribavirin (antiviral drugs against hepatitis C virus) on different body systems in male albino rats regarding reproductive, hematological, biochemical, hepatic, and renal profiles and histopathological changes
Rana A. Ali, Eatemad A. Awadalla, Yahia A. Amin, Samer S. Fouad, Maha Abd-El Baki Ahmed, Mohammed H. Hassan, Emaad Abdel-Kahaar, Rehab H. Abdel-Aziz
Scientific Reports.2024;[Epub] CrossRef
Prediabetes and mild hepatosteatosis are associated with blunted cortisol response to glucagon but not to growth hormone
Ozlem Deveci, Zuleyha Karaca, Fatih Tanriverdi, Kamil Deveci, Aysa Hacioglu, Kursad Unluhizarci, Fahrettin Kelestimur
Annales d'Endocrinologie.2023; 84(2): 254. CrossRef
Evaluación del cortisol plasmático durante el test de ayuno en pacientes con síndrome hipoglucémico por hiperinsulinismo endógeno. Experiencia de 15 años
María Eugenia Gullace, María Victoria Ortuño, Teresa Mabel Canteros, Belén Bosco, Cintia Rodriguez, Javier Giunta, Lucas Costa, Andrea Kozak, Valeria de Miguel, Luis Grosembacher
Endocrinología, Diabetes y Nutrición.2023; 70(10): 634. CrossRef
Evaluation of plasma cortisol during fasting test in patients with endogenous hyperinsulinemic hypoglycemia. Fifteen years experience
María Eugenia Gullace, María Victoria Ortuño, Teresa Mabel Canteros, Belén Bosco, Cintia Rodriguez, Javier Giunta, Lucas Costa, Andrea Kozak, Valeria de Miguel, Luis Grosembacher
Endocrinología, Diabetes y Nutrición (English ed.).2023; 70(10): 634. CrossRef
Cerebrospinal fluid levels of hypothalamic-pituitary-adrenal axis hormones in MCI and dementia due to Alzheimer’s disease: a systematic review
Felipe Duarte-Zambrano, Jorge A. Barrero, Ismena Mockus
Dementia & Neuropsychologia.2023;[Epub] CrossRef
PTEN Deletion in Adult Mice Induces Hypoinsulinemia With Concomitant Low Glucose Levels
Maria Crespo-Masip, Aurora Pérez-Gómez, Carla Guzmán, Sandra Rayego, Nuria Doladé, Alicia García-Carrasco, Ramiro Jover, José Manuel Valdivielso
Frontiers in Endocrinology.2022;[Epub] CrossRef
Beta Blockers can Mask not only Hypoglycemia but also Hypotension
Goran Koracevic, Sladjana Micic, Milovan Stojanovic, Radmila Velickovic Radovanovic, Milan Pavlovic, Tomislav Kostic, Dragan Djordjevic, Nebojsa Antonijevic, Maja Koracevic, Vesna Atanaskovic, Sonja Dakic
Current Pharmaceutical Design.2022; 28(20): 1660. CrossRef
Atherosclerosis Risk Factors in Patients with Reactive Hypoglycemia
Małgorzata Landowska, Agata Żebrowska, Konrad Fajer, Patrycja Adamek, Aleksandra Kruk, Bernadetta Kałuża, Edward Franek
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2022; Volume 15: 3133. CrossRef
Depression with Comorbid Diabetes: What Evidence Exists for Treatments Using Traditional Chinese Medicine and Natural Products?
Yanting Lu, Tao An, Hu Tian, Xueqin Gao, Furong Wang, Shijun Wang, Ke Ma
Frontiers in Pharmacology.2021;[Epub] CrossRef
Hepatocyte-specific glucose-6-phosphatase deficiency disturbs platelet aggregation and decreases blood monocytes upon fasting-induced hypoglycemia
Anouk M. La Rose, Venetia Bazioti, Joanne A. Hoogerland, Arthur F. Svendsen, Anouk G. Groenen, Martijn van Faassen, Martijn G.S. Rutten, Niels J. Kloosterhuis, Bertien Dethmers-Ausema, J. Hendrik Nijland, Gilles Mithieux, Fabienne Rajas, Folkert Kuipers,
Molecular Metabolism.2021; 53: 101265. CrossRef
Effects of tofogliflozin on adrenocorticotropic hormone, renin and aldosterone, and cortisol levels in elderly patients with diabetes mellitus
Toshihiro Higashikawa, Tomohiko Ito, Takurou Mizuno, Keiichirou Ishigami, Kengo Kuroki, Naoto Maekawa, Daisuke Usuda, Takuro Morita, Kazu Hamada, Susumu Takagi, Kento Takeshima, Shinya Yamada, Ryusho Sangen, Toshihide Izumida, Hideyuki Mori, Jun Kiyosawa,
Medicine.2021; 100(45): e27638. CrossRef
Stress, glucocorticoid signaling pathway, and metabolic disorders
Roldan M. de Guia
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2020; 14(5): 1273. CrossRef

Predetermined Anti-Diabetic Drug Regimen Adjustments during Ramadan Fasting: An Observational Study of Safety: Abdallah M. Beano, Mohammad A. Zmaili, Zaid H. Gheith, Ahmad M. Naser, Munther S. Momani, Al-Motassem F. Yousef, Ayman A. Zayed; Endocrinol Metab. 2017;32(2):265-273. Published online June 23, 2017; DOI: https://doi.org/10.3803/EnM.2017.32.2.265

4,036 View
41 Download
10 Web of Science
12 Crossref

Abstract PDF PubReader

Background

Many Muslim type 2 diabetes mellitus (T2DM) patients choose to fast the month of Ramadan despite the possible adverse health effects brought about by the change in dietary habits, among other things. Clinical data regarding the safety of multi-drug regimens during fasting are particularly scarce. The aim of the study was to evaluate the safety of a drug protocol devised by the authors to accommodate Ramadan's dietary changes, involving dose adjustments of four anti-diabetic drug regimens in T2DM patients fasting Ramadan.

Methods

In this prospective, observational, open-label study, 301 T2DM patients who wished to fast Ramadan were followed during Ramadan and the preceding month. The incidence of hypoglycemia, diabetic ketoacidosis (DKA) and non-ketotic hyperosmolar state (NKHS) was monitored. Patients were classified into four groups: A group (those taking metformin, sulfonylurea and insulin [n=33]); B group (metformin and sulfonylurea [n=89]); C group (metformin and insulin [n=96]); and D group (premixed 70/30, glargine or regular insulin [n=82]). During Ramadan, drug doses were adjusted as percentages of their pre-Ramadan values: 75% for sulfonylureas, 75% for glargine, 75% for premixed insulin 70/30 in two doses, and 75% for regular insulin. Metformin was adjusted to a twice-daily regimen.

Results

No cases of DKA or NKHS were reported. Hypoglycemia occurred at a lower rate than pre-Ramadan values in groups C, and D; and a similar rate in groups A, and B.

Conclusion

The data suggested that using the above protocol to adjust the doses of anti-diabetic drugs is safe in T2DM patients in regards to hypoglycemia, DKA, and NKHS.

Citations

Citations to this article as recorded by

Replicating human characteristics: A promising animal model of central fatigue
Yifei Zhang, Zehan Zhang, Qingqian Yu, Bijuan Lan, Qinghuan Shi, Ruting Li, Ziheng Jiao, Weiyue Zhang, Feng Li
Brain Research Bulletin.2024; 212: 110951. CrossRef
Evaluation of physicians' approaches for the management of patients with diabetes during Ramadan in Iraq
Majid Alabbood, Rafid Alameri, Yasameen Alsaffar
Diabetes Research and Clinical Practice.2023; 195: 110188. CrossRef
The physiological changing and the recommended management plans for the diabetic patient during Ramadan fasting; A review article
Abeer Alhaj, Omar F Shatnawi
JAP Academy Journal.2023;[Epub] CrossRef
Incidence of diabetic ketoacidosis does not differ in Ramadan compared to other months and seasons: results from a 6-year multicenter study
Fateen Ata, Adeel Ahmad Khan, Ibrahim Khamees, Mohammed Bashir
Current Medical Research and Opinion.2023; 39(8): 1061. CrossRef
Evidence-based risk factors for major complications during Ramadan fasting in people with diabetes grouped under IDF-DAR risk categories
Rahmatullah, Muhammad Yakoob Ahmedani, Abdul Basit, Shagufta Zia, Imran Hasan, Qazi Masroor, Abrar Shaikh, Jehangir Khan, Waheed Iqbal
Diabetes Research and Clinical Practice.2022; 185: 109234. CrossRef
A Systematic Review of Insulin Management Recommendations to Improve Glycemic Control and Reduce Hypoglycemic Events During Ramadan Fasting in Patients With Insulin-Requiring Type 2 Diabetes
Alexander Kieu, Ashley Iles, Moien AB Khan, Linda Östlundh, Duston Boyd, MoezAlIslam Ezzat Faris
Frontiers in Nutrition.2022;[Epub] CrossRef
The DAR 2020 Global survey: Ramadan fasting during COVID 19 pandemic and the impact of older age on fasting among adults with Type 2 diabetes
Mohamed Hassanein, Zanariah Hussein, Inass Shaltout, Wan Juani Wan Seman, Chin Voon Tong, Nurain Mohd Noor, Mehmet Akif Buyukbese, Lobna El Tony, Gamal Mohamed Shaker, Reem M. Alamoudi, Khadija Hafidh, M. Fariduddin, Mohammed A. Batais, Shehla Shaikh, Pr
Diabetes Research and Clinical Practice.2021; 173: 108674. CrossRef
Effect of Dosage Reduction of Hypoglycemic Multidrug Regimens on the Incidences of Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramaḍān: A Randomized Controlled Trial
Louay Y. Zaghlol, Amir F. Beirat, Justin Z. Amarin, Amro M. Hassoun Al Najar, Yazan Y. Hasan, Abdallah Qtaishat, Michael E. Tierney, Raja Y. Zaghlol, Ayman A. Zayed
Frontiers in Endocrinology.2021;[Epub] CrossRef
Recommendations for management of diabetes during Ramadan: update 2020, applying the principles of the ADA/EASD consensus
Mahmoud Ibrahim, Melanie J Davies, Ehtasham Ahmad, Firas A Annabi, Robert H Eckel, Ebtesam M Ba-Essa, Nuha Ali El Sayed, Amy Hess Fischl, Pamela Houeiss, Hinde Iraqi, Ines Khochtali, Kamlesh Khunti, Shabeen Naz Masood, Safia Mimouni-Zerguini, Samad Shera,
BMJ Open Diabetes Research & Care.2020; 8(1): e001248. CrossRef
Ramadan and Diabetes: A Narrative Review and Practice Update
Syed H. Ahmed, Tahseen A. Chowdhury, Sufyan Hussain, Ateeq Syed, Ali Karamat, Ahmed Helmy, Salman Waqar, Samina Ali, Ammarah Dabhad, Susan T. Seal, Anna Hodgkinson, Shazli Azmi, Nazim Ghouri
Diabetes Therapy.2020; 11(11): 2477. CrossRef
A systematic review on efficacy and safety of the current hypoglycemic agents in patients with diabetes during Ramadan fasting
Fauzia Rashid, Elamin Abdelgadir
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2019; 13(2): 1413. CrossRef
Risk of diabetic ketoacidosis during Ramadan fasting: A critical reappraisal
Salem A. Beshyah, Tahseen A. Chowdhury, Nazim Ghouri, Abdulfattah A. Lakhdar
Diabetes Research and Clinical Practice.2019; 151: 290. CrossRef

Review Articles

Hypoglycemia and Dementia: Sang Youl Rhee; Endocrinol Metab. 2017;32(2):195-199. Published online June 23, 2017; DOI: https://doi.org/10.3803/EnM.2017.32.2.195

4,320 View
67 Download
10 Web of Science
11 Crossref

Abstract PDF PubReader

Recently, cardiovascular morbidity and mortality have been continuously reduced in people with diabetes through the intensive management of multiple risk factors. However, contrary to this trend, the prevalence and clinical significance of neurodegenerative disorders are steadily increasing. In previous studies, diabetes mellitus has been found to play an important role in increasing the risk of dementia and cognitive dysfunction through various mechanisms. In particular, hypoglycemia is a frequent clinical situation in the strict management of diabetes and is well known as an important factor that directly affects the risk of dementia and cognitive impairment. This article describes the occurrence of hypoglycemia in patients with diabetes, and summarizes the resultant risks of dementia and cognitive dysfunction.

Citations

Citations to this article as recorded by

Inhibitor of DNA Binding Protein 3 (ID3) and Nuclear Respiratory Factor 1 (NRF1) Mediated Transcriptional Gene Signatures are Associated with the Severity of Cerebral Amyloid Angiopathy
Christian Michael Perez, Zhenghua Gong, Changwon Yoo, Deodutta Roy, Alok Deoraj, Quentin Felty
Molecular Neurobiology.2024; 61(2): 835. CrossRef
Continuous glucose monitoring assessment in patients suffering from anorexia nervosa reveals chronic prolonged mild hypoglycemia all over the nycthemeron
Natacha Germain, Clara Devin Genteuil, Gwenaëlle Belleton, Trecy Lopes Da Silva, Chloé Exbrayat, Fabien Degas, Amira Hammour, Aurélia Gay, Baptiste Ravey, Catherine Massoubre, Bogdan Galusca
European Eating Disorders Review.2023; 31(3): 402. CrossRef
Protective Potential of β-Hydroxybutyrate against Glucose-Deprivation-Induced Neurotoxicity Involving the Modulation of Autophagic Flux and the Monomeric Aβ Level in Neuro-2a Cells
Yi-Fen Chiang, Ngan Thi Kim Nguyen, Shih-Min Hsia, Hsin-Yuan Chen, Shyh-Hsiang Lin, Ching-I Lin
Biomedicines.2023; 11(3): 698. CrossRef
The effect of first- and second-generation antipsychotics on brain morphology in schizophrenia: A systematic review of longitudinal magnetic resonance studies with a randomized allocation to treatment arms
Konstantinos N Fountoulakis, Stephen M Stahl
Journal of Psychopharmacology.2022; 36(4): 428. CrossRef
Weight-loss induced by carbohydrate restriction does not negatively affect health-related quality of life and cognition in people with type 2 diabetes: A randomised controlled trial
Nicole Jacqueline Jensen, Helena Zander Wodschow, Mads Juul Skytte, Amirsalar Samkani, Arne Astrup, Jan Frystyk, Bolette Hartmann, Jens Juul Holst, Thomas Meinert Larsen, Sten Madsbad, Faidon Magkos, Kamilla Woznica Miskowiak, Steen Bendix Haugaard, Thure
Clinical Nutrition.2022; 41(7): 1605. CrossRef
Amyloid $$upbeta$$ (1–42) peptide impairs mitochondrial respiration in primary human brain microvascular endothelial cells: impact of dysglycemia and pre-senescence
Siva S. V. P. Sakamuri, Venkata N. Sure, Xiaoying Wang, Gregory Bix, Vivian A. Fonseca, Ricardo Mostany, Prasad V. G. Katakam
GeroScience.2022; 44(6): 2721. CrossRef
Analysis of patients with dementia: Use of computer tomographic and vascular risk
Mauricio Sánchez-Barajas, Tirtha Prasad-Mukhopadhyay, José María De la Roca-Chiapas, Teodoro Córdova-Fraga
Revista de Fisioterapia y Tecnología Médica.2022; : 1. CrossRef
The report of the joint WPA/CINP workgroup on the use and usefulness of antipsychotic medication in the treatment of schizophrenia
Konstantinos N. Fountoulakis, Hans-Jurgen Moeller, Siegfried Kasper, Carol Tamminga, Shigeto Yamawaki, Rene Kahn, Rajiv Tandon, Christoph U. Correll, Afzal Javed
CNS Spectrums.2021; 26(6): 562. CrossRef
Target attainment in insulin-naive patients at high risk for hypoglycemia: Results from ACHIEVE Control
John Anderson, Luigi Meneghini, Debbie Hinnen, Jasvinder Gill, Mathieu Coudert, Pierre Evenou, Medha Munshi
Journal of Diabetes and its Complications.2021; 35(4): 107831. CrossRef
Hypoglycemia, Vascular Disease and Cognitive Dysfunction in Diabetes: Insights from Text Mining-Based Reconstruction and Bioinformatics Analysis of the Gene Networks
Olga V. Saik, Vadim V. Klimontov
International Journal of Molecular Sciences.2021; 22(22): 12419. CrossRef
Association between the Use of Dipeptidyl Peptidase 4 Inhibitors and the Risk of Dementia among Patients with Type 2 Diabetes in Taiwan
Kuan-Chan Chen, Chi-Hsiang Chung, Chieh-Hua Lu, Nian-Sheng Tzeng, Chien-Hsing Lee, Sheng-Chiang Su, Feng-Chih Kuo, Jhih-Syuan Liu, Chang-Hsun Hsieh, Wu-Chien Chien
Journal of Clinical Medicine.2020; 9(3): 660. CrossRef

Stepwise Approach to Problematic Hypoglycemia in Korea: Educational, Technological, and Transplant Interventions: Sang-Man Jin; Endocrinol Metab. 2017;32(2):190-194. Published online June 23, 2017; DOI: https://doi.org/10.3803/EnM.2017.32.2.190

3,119 View
34 Download
3 Web of Science
3 Crossref

Abstract PDF PubReader

Impaired awareness of hypoglycemia has been found to be prevalent in 20% to 40% of people with type 1 diabetes. If a similar prevalence exists in Koreans with type 1 diabetes, at a minimum, thousands of people with type 1 diabetes suffer at least one unpredicted episode of severe hypoglycemia per year in Korea. For patients with problematic hypoglycemia, an evidence-based stepwise approach was suggested in 2015. The first step is structured education regarding multiple daily injections of an insulin analog, and the second step is adding a technological intervention, such as continuous subcutaneous insulin infusion or real-time continuous glucose monitoring. The next step is a sensor-augmented pump, preferably with a low glucose suspension feature or very frequent contact, and the final step is islet or pancreas transplantation. In Korea, however, none of these treatments are reimbursed by the National Health Insurance, and thus have not been widely implemented. The low prevalence of type 1 diabetes means that Korean physicians are relatively unfamiliar with the new technologies in this field. Therefore, the roles of new technologies and pancreas or islet transplantation in the treatment of problematic hypoglycemia need to be defined in the current clinical setting of Korea.

Citations

Citations to this article as recorded by

Protective and risk factors of impaired awareness of hypoglycemia in patients with type 1 diabetes: a cross-sectional analysis of baseline data from the PR-IAH study
Naoki Sakane, Ken Kato, Sonyun Hata, Erika Nishimura, Rika Araki, Kunichi kouyama, Masako Hatao, Yuka Matoba, Yuichi Matsushita, Masayuki Domichi, Akiko Suganuma, Seiko Sakane, Takashi Murata, Fei Ling Wu
Diabetology & Metabolic Syndrome.2023;[Epub] CrossRef
A 4-Week, Two-Center, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of EOPatch in Well-Controlled Type 1 Diabetes Mellitus
Jiyun Park, Nammi Park, Sangjin Han, You-Bin Lee, Gyuri Kim, Sang-Man Jin, Woo Je Lee, Jae Hyeon Kim
Diabetes & Metabolism Journal.2022; 46(6): 941. CrossRef
Impaired hypoglycemia awareness in diabetes: epidemiology, mechanisms and therapeutic approaches
Vadim V. Klimontov
Diabetes mellitus.2019; 21(6): 513. CrossRef

Original Articles

Clinical Study
1,5-Anhydro-D-Glucitol Could Reflect Hypoglycemia Risk in Patients with Type 2 Diabetes Receiving Insulin Therapy: Min Kyeong Kim, Hye Seung Jung, Soo Heon Kwak, Young Min Cho, Kyong Soo Park, Seong Yeon Kim; Endocrinol Metab. 2016;31(2):284-291. Published online May 27, 2016; DOI: https://doi.org/10.3803/EnM.2016.31.2.284

4,379 View
41 Download
4 Web of Science
5 Crossref

Abstract PDF PubReader

Background

The identification of a marker for hypoglycemia could help patients achieve strict glucose control with a lower risk of hypoglycemia. 1,5-Anhydro-D-glucitol (1,5-AG) reflects postprandial hyperglycemia in patients with well-controlled diabetes, which contributes to glycemic variability. Because glycemic variability is related to hypoglycemia, we aimed to evaluate the value of 1,5-AG as a marker of hypoglycemia.

Methods

We enrolled 18 adults with type 2 diabetes mellitus (T2DM) receiving insulin therapy and assessed the occurrence of hypoglycemia within a 3-month period. We measured 1,5-AG level, performed a survey to score the severity of hypoglycemia, and applied a continuous glucose monitoring system (CGMS).

Results

1,5-AG was significantly lower in the high hypoglycemia-score group compared to the low-score group. Additionally, the duration of insulin treatment was significantly longer in the high-score group. Subsequent analyses were adjusted by the duration of insulin treatment and mean blood glucose, which was closely associated with both 1,5-AG level and hypoglycemia risk. In adjusted correlation analyses, 1,5-AG was negatively correlated with hypoglycemia score, area under the curve at 80 mg/dL, and low blood glucose index during CGMS (P=0.068, P=0.033, and P=0.060, respectively).

Conclusion

1,5-AG level was negatively associated with hypoglycemia score determined by recall and with documented hypoglycemia after adjusting for mean glucose and duration of insulin treatment. As a result, this level could be a marker of the risk of hypoglycemia in patients with well-controlled T2DM receiving insulin therapy.

Citations

Citations to this article as recorded by

Mobile Healthcare System Provided by Primary Care Physicians Improves Quality of Diabetes Care
Tae Jung Oh, Jie-Eun Lee, Seok Kim, Sooyoung Yoo, Hak Chul Jang
CardioMetabolic Syndrome Journal.2021; 1(1): 88. CrossRef
Effects of mobile phone application combined with or without self‐monitoring of blood glucose on glycemic control in patients with diabetes: A randomized controlled trial
Yuan Yu, Qun Yan, Huizhi Li, Hongmei Li, Lin Wang, Hua Wang, Yiyun Zhang, Lei Xu, Zhaosheng Tang, Xinfeng Yan, Yinghua Chen, Huili He, Jie Chen, Bo Feng
Journal of Diabetes Investigation.2019; 10(5): 1365. CrossRef
Articles inEndocrinology and Metabolismin 2016
Won-Young Lee
Endocrinology and Metabolism.2017; 32(1): 62. CrossRef
A Diet Diverse in Bamboo Parts is Important for Giant Panda (Ailuropoda melanoleuca) Metabolism and Health
Hairui Wang, Heju Zhong, Rong Hou, James Ayala, Guangmang Liu, Shibin Yuan, Zheng Yan, Wenping Zhang, Yuliang Liu, Kailai Cai, Zhigang Cai, He Huang, Zhihe Zhang, De Wu
Scientific Reports.2017;[Epub] CrossRef
Low and exacerbated levels of 1,5-anhydroglucitol are associated with cardiovascular events in patients after first-time elective percutaneous coronary intervention
Shuhei Takahashi, Kazunori Shimada, Katsumi Miyauchi, Tetsuro Miyazaki, Eiryu Sai, Manabu Ogita, Shuta Tsuboi, Hiroshi Tamura, Shinya Okazaki, Tomoyuki Shiozawa, Shohei Ouchi, Tatsuro Aikawa, Tomoyasu Kadoguchi, Hamad Al Shahi, Takuma Yoshihara, Makoto Hi
Cardiovascular Diabetology.2016;[Epub] CrossRef

Obesity and Metabolism
Optimal Candidates for the Switch from Glimepiride to Sitagliptin to Reduce Hypoglycemia in Patients with Type 2 Diabetes Mellitus: Hyun Min Kim, Jung Soo Lim, Byung-Wan Lee, Eun-Seok Kang, Hyun Chul Lee, Bong-Soo Cha; Endocrinol Metab. 2015;30(1):84-91. Published online March 27, 2015; DOI: https://doi.org/10.3803/EnM.2015.30.1.84

5,861 View
98 Download
12 Web of Science
11 Crossref

Abstract PDF PubReader

Background

Sitagliptin is a novel antidiabetic agent with a low risk for hypoglycemia. We investigated the efficacy and safety of sitagliptin when patients switched from a sulfonylurea to sitagliptin and identified good candidates for the switch.

Methods

Sixty-one patients with type 2 diabetes switched from glimepiride with metformin to sitagliptin with metformin due to clinical hypoglycemia. Serum glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), and 2-hour postprandial plasma glucose (2h-PPG) before and 12 and 24 weeks after the drug switch were checked.

Results

HbA1c and FPG levels did not change 12 or 24 weeks after the switch; however, the 2h-PPG level decreased from 218.0±67.5 mg/dL at baseline to 197.1±69.9 mg/dL at 12 weeks and 192.3±67.4 mg/dL at 24 weeks after switching drugs (P=0.045, P=0.018, respectively). All but one patient no longer experienced hypoglycemia after discontinuing glimepiride. In a multivariate logistic regression analysis, a high homeostasis model assessment of insulin resistance and low baseline HbA1c level were independent predictors of an HbA1c ≤7% after switching to sitagliptin.

Conclusion

Glycemic control was not aggravated in patients 24 weeks after the drug switch, and symptomatic hypoglycemia decreased significantly. Patients with dominant insulin resistance may be good candidates for switching from a sulfonylurea to sitagliptin to reduce hypoglycemia.

Citations

Citations to this article as recorded by

Application of Machine Learning Methods for the Development of Antidiabetic Drugs
Juanjuan Zhao, Pengcheng Xu, Xiujuan Liu, Xiaobo Ji, Minjie Li, Dev Sooranna, Xiaosheng Qu, Wencong Lu, Bing Niu
Current Pharmaceutical Design.2022; 28(4): 260. CrossRef
Efficacy and safety of dorzagliatin for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis
Yunfeng Yu, Xingyu Yang, Keke Tong, Shuang Yin, Gang Hu, Fei Zhang, Pengfei Jiang, Manli Zhou, Weixiong Jian
Frontiers in Cardiovascular Medicine.2022;[Epub] CrossRef
Factors associated with switching from sulphonylureas to dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in the United States
Xi Tan, Lingfeng Yang, Kamlesh Khunti, Ruya Zhang, Ye Zhang, Swapnil Rajpathak, Miao Yu
Diabetes, Obesity and Metabolism.2021; 23(10): 2251. CrossRef
Increased risk of adverse cardiovascular events by strict glycemic control after percutaneous coronary intervention (HbA1c < 6.5% at 2 years) in type 2 diabetes mellitus combined with acute coronary syndrome: a 5-years follow-up study
Tiangui Yang, Peng Fu, Jie Chen, Xi Fu, Changlu Xu, Xiaoxia Liu, Tiesheng Niu
Current Medical Research and Opinion.2021; 37(9): 1517. CrossRef
Clinical analysis of pre-existing diabetes mellitus and dipeptidyl peptidase-4 inhibitors in patients with remitting seronegative symmetrical synovitis and pitting edema syndrome
Yoshiro Horai, Tomoki Origuchi, Nozomi Iwanaga, Junichi Tokumitsu, Toshiyuki Ikeoka, Genpei Kuriya, Yasumori Izumi, Atsushi Kawakami
Modern Rheumatology.2020; 30(4): 703. CrossRef
The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials
Juan Ling, Peng Cheng, Long Ge, Ding-hua Zhang, An-chen Shi, Jin-hui Tian, Ya-jing Chen, Xiu-xia Li, Jing-yun Zhang, Ke-hu Yang
Acta Diabetologica.2019; 56(3): 249. CrossRef
Satisfaction and efficacy of switching from daily dipeptidyl peptidase-4 inhibitors to weekly trelagliptin in patients with type 2 diabetes—Randomized controlled study—
Mayuko Oita, Hideaki Miyoshi, Kota Ono, Akinobu Nakamura, Kyu Yong Cho, Hiroshi Nomoto, Kohei Yamamoto, Kazuno Omori, Naoki Manda, Yoshio Kurihara, Shin Aoki, Tatsuya Atsumi
Endocrine Journal.2018; 65(2): 141. CrossRef
Efficacy and safety of evogliptin versus sitagliptin as add on to metformin alone in a combined russian-korean population. Evo-combi trial
Alina Y. Babenko, Anna A. Mosikian, Igor E. Makarenko, Victoriya V. Leusheva, Evgeny V. Shlyakhto
Diabetes mellitus.2018; 21(4): 241. CrossRef
Effectiveness prediction of Evogliptin treatment in type 2 diabetes mellitus in russian-korean population
Anna A. Mosikian, Alina Y. Babenko, Yulia A. Sevastyanova, Roman V. Drai, Evgenij V. Shlyakhto
Diabetes mellitus.2018; 21(5): 333. CrossRef
Comprehensive analysis of the Co-structures of dipeptidyl peptidase IV and its inhibitor
Hiroyuki Nojima, Kazuhiko Kanou, Genki Terashi, Mayuko Takeda-Shitaka, Gaku Inoue, Koichiro Atsuda, Chihiro Itoh, Chie Iguchi, Hajime Matsubara
BMC Structural Biology.2016;[Epub] CrossRef
A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes
Eugene Han, Hye Sun Park, Obin Kwon, Eun Yeong Choe, Hye Jin Wang, Yong-ho Lee, Sang-Hak Lee, Chul Hoon Kim, Lee-Kyung Kim, Soo Heon Kwak, Kyong Soo Park, Chul Sik Kim, Eun Seok Kang
Medicine.2016; 95(44): e5155. CrossRef

Case Report

Obesity and Metabolism
Recurrent Hypoglycemia Triggered by Sorafenib Therapy in a Patient with Hemangiopericytoma: Si Won Lee, Eun Kyung Lee, Tak Yun, Young-Woong Won, Eun Jeong Ko, Mihong Choi, Sang Il Choi, Sun Seob Park, Eun Kyung Hong; Endocrinol Metab. 2014;29(2):202-205. Published online June 26, 2014; DOI: https://doi.org/10.3803/EnM.2014.29.2.202

3,116 View
28 Download
5 Web of Science
5 Crossref

Abstract PDF PubReader

Targeted therapy has been proven to be one of the most effective cancer treatments. However, some endocrine disorders can occur during treatment with targeted agents. We report the case of a patient who exhibited a wax and wane pattern of hypoglycemia that was attributed to sorafenib therapy. A 32-year-old woman with metastatic hemangiopericytoma visited the emergency department in a stuporous state. Nonhyperinsulinemic hypoglycemia was diagnosed, was exacerbated shortly after sorafenib therapy, and was improved by the cessation of sorafenib with additional glucocorticoid therapy. Patients with metastatic hemangiopericytoma should be carefully monitored with particular attention to hypoglycemia when sorafenib therapy is initiated.

Citations

Citations to this article as recorded by

Pazopanib-associated secondary adrenal insufficiency in a patient with malignant solitary fibrous tumor
Muhammed Muhiddin Er, Murat Araz, Meryem Karabacak, Muzaffer Uğraklı, Melek Karakurt Eryılmaz, Mustafa Karaağaç, Mehmet Artaç
Journal of Oncology Pharmacy Practice.2021; 27(8): 2049. CrossRef
Cancer, obesity, and diabetes: TKIs exert multiple effects on glucose homeostasis
Minglin Lin, Junfei Jin
Nature Reviews Clinical Oncology.2017; 14(5): 268. CrossRef
Multidisciplinary Approach to Hepatic Metastases of Intracranial Hemangiopericytoma: A Case Report and Review of the Literature
Dimitrios K. Manatakis, Spiridon G. Delis, Nikolaos Ptohis, Penelope Korkolopoulou, Christos Dervenis
Case Reports in Oncological Medicine.2015; 2015: 1. CrossRef
Articles in 'Endocrinology and Metabolism' in 2014
Won-Young Lee
Endocrinology and Metabolism.2015; 30(1): 47. CrossRef
Case report of severe Cushing’s syndrome in medullary thyroid cancer complicated by functional diabetes insipidus, aortic dissection, jejunal intussusception, and paraneoplastic dysautonomia: remission with sorafenib without reduction in cortisol concentr
Muhammad M. Hammami, Najla Duaiji, Ghazi Mutairi, Sabah Aklabi, Nasser Qattan, Mohei El-Din M. Abouzied, Mohamed W. Sous
BMC Cancer.2015;[Epub] CrossRef

Review Article

Obesity and Metabolism
Neurocognitive Changes and Their Neural Correlates in Patients with Type 2 Diabetes Mellitus: Junghyun H Lee, Yera Choi, Chansoo Jun, Young Sun Hong, Han Byul Cho, Jieun E Kim, In Kyoon Lyoo; Endocrinol Metab. 2014;29(2):112-121. Published online June 26, 2014; DOI: https://doi.org/10.3803/EnM.2014.29.2.112

4,730 View
49 Download
34 Web of Science
31 Crossref

Abstract PDF PubReader

As the prevalence and life expectancy of type 2 diabetes mellitus (T2DM) continue to increase, the importance of effective detection and intervention for the complications of T2DM, especially neurocognitive complications including cognitive dysfunction and dementia, is receiving greater attention. T2DM is thought to influence cognitive function through an as yet unclear mechanism that involves multiple factors such as hyperglycemia, hypoglycemia, and vascular disease. Recent developments in neuroimaging methods have led to the identification of potential neural correlates of T2DM-related neurocognitive changes, which extend from structural to functional and metabolite alterations in the brain. The evidence indicates various changes in the T2DM brain, including global and regional atrophy, white matter hyperintensity, altered functional connectivity, and changes in neurometabolite levels. Continued neuroimaging research is expected to further elucidate the underpinnings of cognitive decline in T2DM and allow better diagnosis and treatment of the condition.

Citations

Citations to this article as recorded by

The level of serum retinol-binding protein is associated with diabetic mild cognitive impairment
Wenjie Zhang, Yuqi Yuan, Xiaoxia Cui, Shihong Chen, Xianghua Zhuang
Brain Research.2024; 1822: 148670. CrossRef
Research Progress on Lipocalin-2 in Diabetic Encephalopathy
Wenjie Zhang, Shihong Chen, Xianghua Zhuang
Neuroscience.2023; 515: 74. CrossRef
Voluntary Attention and Quality of Life in Patients With Type 1 and Type 2 Diabetes Mellitus: Differences in Changes Depending on Disease Type and Duration
N. E. Tadevosyan, A. S. Khachunts, M. Gohargani, A. A. Sahakyan, A. A. Tumanyan
Journal of Evolutionary Biochemistry and Physiology.2022; 58(2): 569. CrossRef
Modifiable risk factors for neurocognitive and psychosocial problems after Hodgkin lymphoma
AnnaLynn M. Williams, Sedigheh Mirzaei Salehabadi, Mengqi Xing, Nicholas S. Phillips, Matthew J. Ehrhardt, Rebecca Howell, Yutaka Yasui, Kevin C. Oeffinger, Todd Gibson, Eric J. Chow, Wendy Leisenring, Deokumar Srivastava, Melissa M. Hudson, Leslie L. Rob
Blood.2022; 139(20): 3073. CrossRef
Type 2 Diabetes Independent of Glycemic Control is Associated With Cognitive Impairments: Findings From NHANES
Rozmin Jiwani, Brittany Dennis, Alfonso L. Neri, Chandler Bess, Sara Espinoza, Jing Wang, Monica C. Serra
Clinical Nursing Research.2022; 31(7): 1225. CrossRef
Diabetes and associated cognitive disorders: Role of the Hypothalamic-Pituitary Adrenal axis
Nathalie Marissal-Arvy, Marie-Pierre Moisan
Metabolism Open.2022; 15: 100202. CrossRef
Inside the diabetic brain: Insulin resistance and molecular mechanism associated with cognitive impairment and its possible therapeutic strategies
Bhaskar Jyoti Dutta, Shamsher Singh, Sanket Seksaria, Ghanshyam Das Gupta, Amrita Singh
Pharmacological Research.2022; 182: 106358. CrossRef
The role of LRP1 in Aβ efflux transport across the blood-brain barrier and cognitive dysfunction in diabetes mellitus
Xue P, Long Zz, Jiang Gg, Wang Lp, Bian Cm, Wang Yl, M.F. Chen, Li W
Neurochemistry International.2022; 160: 105417. CrossRef
Childhood Neurotoxicity and Brain Resilience to Adverse Events during Adulthood
AnnaLynn M. Williams, Yin Ting Cheung, Geehong Hyun, Wei Liu, Kirsten K. Ness, Matthew J. Ehrhardt, Daniel A. Mulrooney, Nickhill Bhakta, Pia Banerjee, Tara M. Brinkman, Daniel M. Green, Wassim Chemaitilly, I‐Chan Huang, Deokumar Srivastava, Melissa M. Hu
Annals of Neurology.2021; 89(3): 534. CrossRef
Metformin restores hippocampal neurogenesis and learning and memory via regulating gut microbiota in the obese mouse model
Xiaoyi Ma, Wenchang Xiao, Hao Li, Pei Pang, Feixiao Xue, Lu Wan, Lei Pei, Huanhuan Yan
Brain, Behavior, and Immunity.2021; 95: 68. CrossRef
Promoting Successful Cognitive Aging: A Ten-Year Update
Taylor J. Krivanek, Seth A. Gale, Brittany M. McFeeley, Casey M. Nicastri, Kirk R. Daffner
Journal of Alzheimer's Disease.2021; 81(3): 871. CrossRef
Association of Vitamin D Level and Nerve Conduction Study Parameters with Cognitive Function in Diabetic Neuropathy Patients
Aida Fithrie, Fasihah Irfani Fitri, Muhammad Reza Putra
Open Access Macedonian Journal of Medical Sciences.2021; 9(B): 72. CrossRef
Insulin resistance takes center stage: a new paradigm in the progression of bipolar disorder
Cynthia V. Calkin
Annals of Medicine.2019; 51(5-6): 281. CrossRef
Vitamin D Supplementation and Cognition in People with Type 2 Diabetes: A Randomized Control Trial
Mary A. Byrn, William Adams, Sue Penckofer, Mary Ann Emanuele
Journal of Diabetes Research.2019; 2019: 1. CrossRef
Neurocognitive impairment in type 2 diabetes mellitus
Marianna Karvani, P. Simos, S. Stavrakaki, D. Kapoukranidou
Hormones.2019; 18(4): 523. CrossRef
Benefits of combination low-dose pioglitazone plus fish oil on aged type 2 diabetes mice
Yuzuru Iizuka, Hyounju Kim, Satoshi Hirako, Kanako Chiba, Masahiro Wada, Akiyo Matsumoto
Journal of Food and Drug Analysis.2018; 26(4): 1265. CrossRef
Association of ApoE Genetic Polymorphism and Type 2 Diabetes with Cognition in Non-Demented Aging Chinese Adults: A Community Based Cross-Sectional Study
Jie Zhen, Tong Lin, Xiaochen Huang, Huiqiang Zhang, Shengqi Dong, Yifan Wu, Linlin Song, Rong Xiao, Linhong Yuan
Aging and disease.2018; 9(3): 346. CrossRef
Chronic Health Conditions and Neurocognitive Function in Aging Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study
Yin Ting Cheung, Tara M Brinkman, Chenghong Li, Yasmin Mzayek, Deokumar Srivastava, Kirsten K Ness, Sunita K Patel, Rebecca M Howell, Kevin C Oeffinger, Leslie L Robison, Gregory T Armstrong, Kevin R Krull
JNCI: Journal of the National Cancer Institute.2018; 110(4): 411. CrossRef
Diabetes, Depression, and Cognition: a Recursive Cycle of Cognitive Dysfunction and Glycemic Dysregulation
Sheila Black, Kyle Kraemer, Avani Shah, Gaynell Simpson, Forrest Scogin, Annie Smith
Current Diabetes Reports.2018;[Epub] CrossRef
Hypoglycemia is associated with dementia in elderly patients with type 2 diabetes mellitus: An analysis based on the Korea National Diabetes Program Cohort
Sang Ouk Chin, Sang Youl Rhee, Suk Chon, Sei Hyun Baik, Yongsoo Park, Moon Suk Nam, Kwan Woo Lee, Ki Hong Chun, Jeong-taek Woo, Young Seol Kim
Diabetes Research and Clinical Practice.2016; 122: 54. CrossRef
Bipolar disorders, type 2 diabetes mellitus, and the brain
Tomas Hajek, Roger McIntyre, Martin Alda
Current Opinion in Psychiatry.2016; 29(1): 1. CrossRef
1,5-Anhydro-D-Glucitol Could Reflect Hypoglycemia Risk in Patients with Type 2 Diabetes Receiving Insulin Therapy
Min Kyeong Kim, Hye Seung Jung, Soo Heon Kwak, Young Min Cho, Kyong Soo Park, Seong Yeon Kim
Endocrinology and Metabolism.2016; 31(2): 284. CrossRef
Insulin in the nervous system and the mind: Functions in metabolism, memory, and mood
Seung-Hwan Lee, Janice M. Zabolotny, Hu Huang, Hyon Lee, Young-Bum Kim
Molecular Metabolism.2016; 5(8): 589. CrossRef
Toll-like receptor 2 and type 2 diabetes
Zahra Sepehri, Zohre Kiani, Ali Akbar Nasiri, Farhad Kohan
Cellular & Molecular Biology Letters.2016;[Epub] CrossRef
Long-term Variability in Glycemic Control Is Associated With White Matter Hyperintensities in APOE4 Genotype Carriers With Type 2 Diabetes
Abigail Livny, Ramit Ravona-Springer, Anthony Heymann, Rachel Priess, Tammar Kushnir, Galia Tsarfaty, Leeron Rabinov, Reut Moran, Hadass Hoffman, Itzik Cooper, Lior Greenbaum, Jeremy Silverman, Mary Sano, Sterling C. Johnson, Barbara B. Bendlin, Michal Sc
Diabetes Care.2016; 39(6): 1056. CrossRef
DIABETES MELLITUS Y SU ASOCIACIÓN CON DETERIORO COGNITIVO Y DEMENCIA
Gonzalo Muñoz A., Christina Degen, Johannes Schröder, Pablo Toro E.
Revista Médica Clínica Las Condes.2016; 27(2): 266. CrossRef
Blood electrolyte disturbances during severe hypoglycemia in Korean patients with type 2 diabetes
Mi Yeon Kang
The Korean Journal of Internal Medicine.2015; 30(5): 648. CrossRef
Whenever You Lose Connection, Take Intranasal Insulin?
Antje Gottschalk, Björn Ellger
Diabetes.2015; 64(3): 687. CrossRef
Spatial Patterns of Structural Brain Changes in Type 2 Diabetic Patients and Their Longitudinal Progression With Intensive Control of Blood Glucose
Guray Erus, Harsha Battapady, Tianhao Zhang, James Lovato, Michael E. Miller, Jeff D. Williamson, Lenore J. Launer, R. Nick Bryan, Christos Davatzikos
Diabetes Care.2015; 38(1): 97. CrossRef
Articles in 'Endocrinology and Metabolism' in 2014
Won-Young Lee
Endocrinology and Metabolism.2015; 30(1): 47. CrossRef
Cerebrolysin reverses hippocampal neural atrophy in a mice model of diabetes mellitus type 1
Lizzette Sanchez‐Vega, Ismael Juárez, Maria De Jesus Gomez‐Villalobos, Gonzalo Flores
Synapse.2015; 69(6): 326. CrossRef

First
Prev
Page of 2
Next
Last

Search